ArticleCancer management and research2025
Elevated Levels of MUC and JADE1 Predict Poor Prognosis of Patients with Gastric Cancer.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the relationship between the expression of mucin (MUC) and JADE family PHD finger factor 1 (JADE1) and Methods: According to the results of immunohistochemical staining, 132 gastric cancer patients diagnosed and treated in our hospital from March 2018 to May 2019 were divided into MUC2 negative group (n=43), MUC2 positive group (n=89), JADE1 negative group (n=36) and JADE1 positive group (n=96). The relationship between MUC2 and JADE1 expression and clinicopathological features of gastric cancer was analyzed. The diagnostic value of MUC2 and JADE1 alone or in combination in gastric cancer was analyzed using ROC curve. Results: The MUC2 and JADE1 expressions in gastric cancer tissues was increased (P<0.05). MUC2 and JADE1 expressions were related to different tumor size, differentiation degree, HP infection, lymph node metastasis, depth of tumor invasion and Lauren classification (P<0.05). Kaplan-Meier survival analysis showed that the survival rate of patients with negative expression of MUC2 and JADE1 was significantly lower than that of patients with positive expression of MUC2 and JADE1 (P<0.05). The area under the curve, sensitivity and specificity of MUC2 alone, JADE1 alone and the two combined in detection of gastric cancer was 0.774, 72.46% and 80.03%, 0.796, 82.14% and 76.48%, and 0.918, 91.34% and 89.57%, respectively. Conclusion: The expressions of MUC2 and JADE1 in gastric cancer tissues were significantly increased, and their expressions were associated with tumor size, differentiation degree, HP infection, lymph node metastasis, depth of tumor infiltration, Lauren's staging. The combined detection of the two has a high value in the diagnosis of gastric cancer. Analysis of the relationship between MUC2 and JADE1 expression and HP infection is helpful for clinical medical staff to effectively evaluate the condition of patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.